Study of 23ME-01473 in Patients With Advanced Solid Malignancies - Trial NCT06290388
Access comprehensive clinical trial information for NCT06290388 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by 23andMe, Inc. and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 82 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
23andMe, Inc.
Timeline & Enrollment
Phase 1/2
Mar 07, 2024
Jun 30, 2026
Primary Outcome
Phase 1:Incidence and severity of dose-limiting toxicities (DLTs),Phase 1: Incidence and severity of adverse events (AEs),Phase 1 Incidence and severity of serious adverse events (SAEs),ORR based on investigator assessment against RECIST 1.1 criteria
Summary
This is a first-in-human open-label study to evaluate the safety, tolerability,
 pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-01473 given by
 intravenous infusion in participants with advanced solid cancers who have progressed or are
 intolerant of available standard therapies.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06290388
Non-Device Trial